Robert S. Alter, MD

Unmet Needs in the Management of Advanced RCC

June 22nd 2022

Drs Alter and Diamond muse about the unmet needs in advanced RCC treatment.

Cabozantinib + Nivolumab Regimen in the Treatment of Advanced RCC

June 22nd 2022

A discussion on the role of the cabozantinib and nivolumab regimen in the treatment of advanced RCC.

Patient Profile Presentation: A 56-Year-Old Man with Clear Cell RCC

June 16th 2022

Robert Alter, MD, presents the patient profile of a 56-year-old man with clear cell renal cell carcinoma presenting with hip and leg pain.

Advanced RCC Patient Referrals from Community Oncologists

June 16th 2022

Elan Diamond, MD, describes when and how often community oncologists refer patients with suspected advanced renal cell carcinoma to his practice.

Nivolumab + Ipilimumab Combination Regimen for Advanced RCC

June 8th 2022

Oncologists review the IO/IO combination regimens available for treatment of advanced RCC and discuss patient selection for treatment with nivolumab and ipilimumab.

Patient Profile Presentation: A 70-Year-Old Man with Stage 4 Clear Cell RCC

June 8th 2022

Dr Elan Diamond presents the patient profile of a 70-year-old man with stage IV clear cell renal cell carcinoma.

Sequencing Therapies for Advanced RCC

June 2nd 2022

Experts discuss how they sequence I/O–TKI treatments for advanced renal cell carcinoma.

Toxicities with IO-TKI Combination Regimens for Advanced RCC and Their Management

June 2nd 2022

Elan Diamond, MD, explains toxicities commonly seen with I/O–TKI combination regimens, how to manage them, and how to discuss toxicities with patients with advanced renal cell carcinoma.

Front-Line Lenvatinib + Pembrolizumab Combination Regimens for Advanced RCC: Selecting Patients and Dose

May 25th 2022

A review of the first-line I/O-TKI combination regimens available for advanced RCC and selecting the right patients and dose for treatment with lenvatinib and pembrolizumab.

Patient Profile Presentation: A 56-Year-Old Man with Metastatic Clear Cell RCC

May 25th 2022

Robert Alter, MD, presents the patient profile of a 56-year-old man with metastatic clear cell renal cell carcinoma presenting with chromaturia.

Dr. Alter Discusses Provenge MOA and Tolerability

December 2nd 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Alter Discusses the Provenge Treatment Process

November 17th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Alter Discusses the Immunotherapy Provenge

November 11th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Dr. Alter on Trials and Ongoing Research in Kidney Cancer

March 21st 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.

Dr. Alter on Kidney Injury in Relation to Patient Recovery

March 14th 2011

Dr. Robert Alter on ASCO GU-Kidney Cancer Findings

March 14th 2011

Dr. Alter on 2011 ASCO GU Prostate Cancer Findings

March 14th 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.

Dr. Alter Discusses Research at JTCC

March 14th 2011

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Dr. Alter on Kidney Cancer Drugs From 2005-2010

March 14th 2011

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.